AA
DALS

Ancora Advisors’s DA32 Life Science Tech Acquisition Corp. Class A Common Stock DALS Stock Holding History

Ancora Advisors’s Portfolio DALS Stock Details DALS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-600
Closed -$6K – 2490
2022
Q1 		$6K Hold
600
– – ﹤0.01% 1922
2021
Q4 		$6K Hold
600
– – ﹤0.01% 2001
2021
Q3 		$6K Buy
+600
New +$5.93K ﹤0.01% 1870

Other funds holding DALS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Ancora Advisors's DALS Position: Q2 2022 in Review

Ancora Advisors sold out of DA32 Life Science Tech Acquisition Corp. Class A Common Stock (DALS) in Q2 2022, closing a stake of 600 shares — an estimated $6K sold.

Ancora Advisors first reported a position in DALS in Q3 2021 and held it in 3 quarters. The position peaked at $6K in Q1 2022. 45 funds tracked by Wall St. Rank hold DALS as of Q2 2022.

  • Ancora Advisors reported no remaining DA32 Life Science Tech Acquisition Corp. Class A Common Stock position as of Q2 2022 after selling out during the quarter.
  • Ancora Advisors sold 600 DA32 Life Science Tech Acquisition Corp. Class A Common Stock shares in Q2 2022, an estimated $6K.
  • Ancora Advisors first reported a position in DA32 Life Science Tech Acquisition Corp. Class A Common Stock in Q3 2021 and held it in 3 quarters.
  • Ancora Advisors's DA32 Life Science Tech Acquisition Corp. Class A Common Stock position peaked at $6K in Q1 2022.
  • 45 funds tracked by Wall St. Rank held DA32 Life Science Tech Acquisition Corp. Class A Common Stock as of Q2 2022.

Based on Ancora Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.